Poster Abstracts • OFID 2018:5 (Suppl 1) • S175 and after CDI events. The CDPH HAI Program is using these analyses to inform CDI prevention outreach to California healthcare facilities and provider networks.
Background. Diagnosis of Clostridium difficile infection (CDI) is challenging.
The reason is two-fold: (a) lack of unique symptoms and (b) lack of a gold standard test for CDI. We studied variation in CDI rates when different diagnostic algorithms were utilized. In addition, we compared patients who met the clinical definition of CDI with different diagnostic assays.
Methods. This is a retrospective study at an academic medical center (401-bed) conducted over 12 months (January 2017 -December 2017 . A stool sample that tested positive by polymerase chain reaction (PCR) for C. difficile (n = 81) was then tested for glutamate dehydrogenase (GDH) and toxin enzyme immunoassay (EIA). Additionally, all PCR-positive cases were also tested for toxin production by cytotoxic neutralization assay (CCNA). Clinical C. difficile was defined as three or more loose stools within 24-hour time period. Clinical data were obtained from review of charts. This definition was applied to all community-onset and hospital-onset cases.
Results. C. difficile was detected in 81 symptomatic patients by PCR test. Of these, 41.9% met the clinical definition of diarrhea. Of the 81 patients, toxin EIA and GDH were positive in 29.6% (24/81) and 4% met the clinical definition. CCNA was positive in 66.67% (54/81) and only 9% met the clinical definition. The CDI rate (per 10,000 patient days) was 10.2 in the PCR positive group; 3.02 in toxin EIA and GDH group and 6.81 in CCNA group. Duration of diarrhea was longer when functional assays (toxin EIA and/or CCNA) were positive, i.e., 48 hours after diagnosis, 22.7% (18/79) of patients with a positive CCNA and EIA had diarrhea while only 6% (3/49) of the patients with GDH and PCR positive tests (nonfunctional assays) had diarrhea (P = 0.013). The difference was statistically significant. All 81 patients were started on CDI treatment within 24 hours of diagnosis. Of note, there was no laxative use contributing to symptoms in these cases.
Conclusion. CDI rates differ with various diagnostic algorithms. Duration of diarrhea was significantly longer when functional assays (CCNA or toxin EIA) were positive. Inclusion of both a functional assay (EIA and/or CCNA) and a clinical definition of CDI can improve the diagnostic accuracy of CDI. A combination of clinical judgment and functional assays is required for an accurate diagnosis of CDI.
Disclosures.All authors: No reported disclosures. There has been a slow and continuous increase in the incidence rate of hospitalized CA-CDI since 2007 without any known obvious explanation. The objectives of this study were to characterize cases of CA-CDI and investigate the potential causes of this increase.
Validation and Characterization of Community-Acquired
Methods. A retrospective study was carried out using a survey sent to eligible healthcare institutions. Hospitals participating in QCISP that reported ≥3 cases of CA-CDI in 2016-2017 were invited to participate. To identify potential causes of the apparent increase in CA-CDI incidence, they were asked to provide clinical information regarding up to three cases of CA-CDI for two distinct surveillance years (2011-2012 and 2016-2017) . To characterize each CA-CDI cases, a broad range of demographic, clinical, and laboratory variables were collected, including medical history, history of contact with primary and secondary healthcare institutions, previous antibiotics use as well as laboratory diagnostic test. A χ 2 test have been used to test year differences in indicator distributions.
Results. A total of 49 healthcare institutions provided data on 172 cases of CA-CDI. Overall, 92% (n = 159) of them meet the QCISP CA-CDI criteria definition. Among them, most patients (67%) were female, and average age was 66.7 ± 20.5 year old. Seventy-four percent had received antibiotic in the previous year. Between the two years, there was no significant change in the socio-demographic and clinical variables of CA-CDI cases. The proportion of patients receiving immunosuppressive drugs and proton pump inhibitors at the time of diagnosis was 11% and 45%, respectively. The proportion of cases visiting ambulatory healthcare settings during the year previous to patient admission increased from 61% (2011-2012) to 69% (2016-2017) (P = 0.18). Moreover, there was a significant increase in the proportion of CA-CDI diagnosed by laboratory PCR test (from 8% to 55%; P < 0.0001).
Conclusion. This study provided important data to characterize CA-CDI using the QCISP. The increase in the use of PCR is associated with the incidence of CA-CDI but may not be the cause of it. Background. Antibiotic use is a well-known risk factor for development of CDI, and there is preliminary evidence suggesting concomitant antibiotic use may result in poor outcomes, including death. This work investigated the effect of concomitant antibiotic exposure during CDI treatment on mortality among patients with CDI.
Methods. We conducted a national retrospective study of Veterans with a first CDI between 2010 and 2014, defined as a positive C. difficile toxin(s) and no episode in the year prior. Those treated with guideline recommended CDI treatment were included (10-14 days of PO or IV metronidazole, PO or PR vancomycin, or fidaxomicin). The exposure of interest was any non-CDI antibiotic use during CDI treatment; and the outcome was all cause death within 30 days of the end of CDI treatment. Inverse probability of treatment weighted Cox proportional hazards models were used to estimate the effect of concomitant antibiotic use on time to mortality. Weights were derived from propensity score modeling of the probability of exposure to antibiotics during CDI treatment as a function of potential confounders. Sensitivity analyses by antibiotic class were conducted.
Results. Of the 9,517 patients included in the study cohort, mean age was 65.3 years (±SD 14.6), 92.5% (n = 8,802) were male, and 75.03% (n = 7,141) were white. Half were exposed to non-CDI antibiotics during CDI treatment (51.8%, n = 4,925) and 8.9% (n = 849) died. In unadjusted and adjusted analyses, concomitant antibiotic use was associated with death (HR 5.74, 95% CI 4.75-6.93; aHR 2.39, 95% CI 2.07-2.75). Advanced generation cephalosporin (aHR 2.36, 95% CI 2.05-2.71), β-lactam/β-lactamase inhibitor combinations (aHR 1.45, 95% CI 1.16-1.82), and clindamycin (aHR 1.95, 95% CI 1.26-3.02) were associated with death, while fluoroquinolone use was not (aHR 0.97, 95% CI 0.84-1.12)
Conclusion. Among our national cohort, concomitant antibiotic use was common during CDI treatment. Any concomitant antibiotic use increased the risk of death; however, results suggest risk might vary by antibiotic class. Results support continued efforts in the reduction of unnecessary antibiotic use during CDI treatment, and future studies into which antibiotics may have the least risk of death when treatment is necessary.
Disclosures Background. The estimated prevalence of Clostridioides difficile infection (CDI) in several South Asian countries is 10.5%, similar to that in North America and Europe. However, the epidemiology of CDI in Bangladesh is unknown. We aimed to assess the prevalence of CDI and assess hospital environmental contamination of toxigenic C. difficile in Bangladesh.
Methods. This was a prospective observational cohort study at two large tertiary care centers in Dhaka, Bangladesh, conducted from January 2017 to December 2017. Stool samples were collected from hospitalized adults with diarrhea (≥3 loose stools in a 24-hour period) and antimicrobial exposure within the past 30 days. Hospital environmental samples were collected by swabbing surfaces of common areas in the hospital. All samples underwent toxigenic culture. C. difficile isolates were tested for toxins A and B and PCR-ribotyped.
Results. Of 204 stool samples collected, 16 (7.8%) were positive for toxigenic C. difficile. Patients with CDI shared a room with significantly more patients (Table 1) . Of 392 environmental samples, 48 (12.2%) were positive for toxigenic C. difficile, which was more common in patient care vs. nonpatient care areas (14.4% vs. 7.8%, P = 0.057). Twelve clinical stool isolates and 42 environmental isolates were ribotyped. Ribotypes identified in stool isolates were F017 (50%), FP053-163 (17%), FP435 (17%), F106 (8%), and F014-020 (8%). With the exception of FP435, these were also the most common ribotypes in environmental isolates: F017 (24%), FP053-163 (12%), F106 (26%), and F014-020 (10%).
Conclusion. For the first time, we report the prevalence of CDI and ribotypes in at risk patients in Bangladesh. Rates and ribotypes are similar to other resource-rich or resource-limited countries. 
